Mavacamten

Mavacamten
Names
Trade namesCamzyos
Other namesMYK-461
IUPAC name
  • 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione
Clinical data
Drug classCardiac myosin inhibitor
Main usesHypertrophic obstructive cardiomyopathy (HCOM)[1]
Side effectsDizziness, syncope[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		By mouth
External links
AHFS/Drugs.comMonograph
Legal
License data
Legal status
Chemical and physical data
FormulaC15H19N3O2
Molar mass273.336 g·mol−1
3D model (JSmol)
SMILES
  • CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O
InChI
  • InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
  • Key:RLCLASQCAPXVLM-NSHDSACASA-N

Mavacamten, sold under the brand name Camzyos, is a medication used to treat hypertrophic obstructive cardiomyopathy (HCOM).[1] It is taken by mouth.[1]

Common side effects include dizziness and syncope.[1] Other side effects may include heart failure.[1] Use in pregnancy may harm the baby.[1] It is a cardiac myosin inhibitor.[1]

Mavacamten was approved for medical use in the United States in 2022.[1] It is not available in Europe or the United Kingdom as of 2022.[3] In the United States a month of medication costs about 7,800 USD.[4]

Medical uses

Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.[1]

Dosage

It is started at a dose of 5 mg once per day, with long term doses between 2.5 and 15 mg once per day.[1]

History

Mavacamten was granted orphan drug designation by the U.S. Food and Drug Administration (FDA).[5] It was developed by the MyoKardia, a subsidiary of Bristol Myers Squibb.[6]

Society and culture

Names

Mavacamten is the international nonproprietary name (INN).[7]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 "Camzyos- mavacamten capsule, gelatin coated". DailyMed. 28 April 2022. Archived from the original on 3 July 2022. Retrieved 15 May 2022.
  2. ↑ "Archive copy". Archived from the original on 2022-11-13. Retrieved 2022-11-29.{{cite web}}: CS1 maint: archived copy as title (link)
  3. ↑ "Mavacamten". SPS - Specialist Pharmacy Service. 19 October 2018. Archived from the original on 24 June 2022. Retrieved 12 December 2022.
  4. ↑ "Camzyos Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 22 May 2023. Retrieved 12 December 2022.
  5. ↑ "Mavacamten Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 27 April 2016. Archived from the original on 3 July 2022. Retrieved 29 April 2022.
  6. ↑ "Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company's Leading Cardiovascular Franchise". Business Wire. 17 November 2020. Archived from the original on 29 April 2022. Retrieved 29 April 2022.
  7. ↑ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.

Further reading

External sites:
Identifiers:
  • Clinical trial number NCT03470545 for "Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM)" at ClinicalTrials.gov
This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.